MedTrace Logo

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

NCT06496620 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2026-03-23

No results posted yet for this study

Summary

A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

Interventions

BIOLOGICAL

Biological: Solrikitug low dose

Solrikitug subcutaneous injection

BIOLOGICAL

Biological: Solrikitug high dose

Solrikitug subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Sponsors & Collaborators

  • DevPro Biopharma

    collaborator INDUSTRY

  • Uniquity One (UNI)

    lead INDUSTRY

Principal Investigators

  • Andrew W Lee, MD · Vice President, Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-14
Primary Completion
2026-06-30
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06496620 on ClinicalTrials.gov